SensL develops silicon detectors that detect extremely low levels of light. This technology has applications from astronomy to environmental protection, health diagnostics, medical analysis, bio-medical research and many more.
It affords potential for a new generation of medical imaging systems enabling the early detection of cancer and other ailments. SensL's photon counting technology produces the most sensitive light detection sensors available in the world - able to detect individual photons of light.
Joseph O'Keeffe, CEO of SensL, said Delta came on board while the technology was still in the NMRC and funded a feasibility study to assess the commercial potential for the technology. "Now they are the lead investor in this round of funding. Delta is the most active early stage investor in Ireland and brings vast expertise in the life sciences sector."